Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology

Kyle LaHucik

Senior Reporter

An 18-month-old Florida biotech has raised a $50 million Series A to wade into the hot immunology and inflammation (I&I) field with oral small molecules.

Forward Therapeutics unveiled the financing from BVF Partners, RA Capital Management and OrbiMed on Wednesday morning. The startup will use the funds to gather Phase I data within three years for its lead drug candidate, CEO Toufike Kanouni told Endpoints News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work

Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir's C-suite

Pharma companies soften tone on full IRA impact

ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to full approval

FDA asks for more data on Dupixent in COPD in move that could delay a decision

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

For­ward Ther­a­peu­tics, the first biotech from Curie.Bio, rais­es $50M for oral small mol­e­cules in im­munol­o­gy

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Lon­nel Coats an­nounces re­tire­ment from Lex­i­con; An­oth­er shake­up in Vir's C-suite

Phar­ma com­pa­nies soft­en tone on full IRA im­pact

ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology

Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work

Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir's C-suite

Pharma companies soften tone on full IRA impact

ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to full approval

FDA asks for more data on Dupixent in COPD in move that could delay a decision

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations